GPRC5D/BCMA/CD3-targeting T-cell engager IBI3003
Term · Oncology and biomedicine · MLC-T-ONC-014026
A T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, with potential antineoplastic activity. Upon administration, GPRC5D/BCMA/CD3-targeting TCE IBI3003 binds to CD3 expressed on T cells, and BCMA and GPRC5D expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA- and GPRC5D-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell proliferation and survival. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.
| Identifier | MLC-T-ONC-014026 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | GPRC5D/BCMA/CD3-targeted agent IBI3003; GPRC5D/BCMA/CD3-targeting agent IBI3003; GPRC5D/BCMA/CD3-targeting TCE IBI3003; T-cell engager IBI3003; TCE IBI3003 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014026",
"term": "GPRC5D/BCMA/CD3-targeting T-cell engager IBI3003",
"field": "Oncology and biomedicine",
"definition": "A T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, with potential antineoplastic activity. Upon administration, GPRC5D/BCMA/CD3-targeting TCE IBI3003 binds to CD3 expressed on T cells, and BCMA and GPRC5D expressed on tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against BCMA- and GPRC5D-expressing tumor cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA, found on the surfaces of plasma cells and overexpressed on malignant plasma cells, plays a key role in plasma cell proliferation and survival. GPRC5D is overexpressed in certain malignancies, such as multiple myeloma, while minimally expressed in normal, healthy cells. It plays a key role in tumor cell proliferation.",
"synonyms": [
"GPRC5D/BCMA/CD3-targeted agent IBI3003",
"GPRC5D/BCMA/CD3-targeting agent IBI3003",
"GPRC5D/BCMA/CD3-targeting TCE IBI3003",
"T-cell engager IBI3003",
"TCE IBI3003"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/gprc5d-bcma-cd3-targeting-t-cell-engager-ibi3003/"
}
Record 8,154 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.